RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 158 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.85 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $721 | +12.1% | 96,474 | 0.0% | 0.32% | +47.7% |
| Q1 2023 | $643 | -13.6% | 96,474 | 0.0% | 0.22% | -18.2% |
| Q4 2022 | $744 | -99.9% | 96,474 | +72.7% | 0.27% | +24.0% |
| Q3 2022 | $594,000 | +379.0% | 55,850 | +266.8% | 0.22% | +352.1% |
| Q2 2022 | $124,000 | +13.8% | 15,225 | 0.0% | 0.05% | +100.0% |
| Q1 2022 | $109,000 | -76.6% | 15,225 | -43.9% | 0.02% | -60.0% |
| Q4 2021 | $465,000 | – | 27,123 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
| Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
| MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
| MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
| ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
| Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
| ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
| Artal Group S.A. | 960,204 | $7,403 | 0.41% |